Diabetes and prediabetes pose a growing global health challenge. Despite strong evidence that lifestyle modification and pharmacologic interventions, such as metformin, reduce diabetes incidence, real-world uptake of prevention programs remains low. Insulin resistance is the mechanistic driver of prediabetes, type 2 diabetes and related complications. Given the increasing number of people affected by insulin resistance and diabetes, there is a large heterogeneity in the phenotypes of the disease, as well as in the organ damages. Therefore, an in-depth knowledge of the disease is crucial to allowing a personalized clinical approach. This program has been designed to improve the understanding of the disease and to provide tools for early treatment, with the final aim of decreasing the burden of diabetes complications, both classical and non-classical ones.
Mikael Ryden
